Sigma-Genosys and Compugen Introduce Genome Libraries For High Throughput Analysis of Gene Function
Sigma-Genosys, a member of the Sigma-Aldrich family (NASDAQ:SIAL), and Compugen (NASDAQ:CGEN) announced today the commercial launch of OligoLibraries(TM), co-branded genome oligonucleotide collections for gene expression profiling, at the 13th International genome sequencing and Analysis Conference (GSAC) in San Diego.
In June 2001, the two companies announced an alliance for the design, manufacture and commercialization of three designated OligoLibraries representing the mouse, rat and human genome. Compugen leverages its LEADS(TM) platform and DNA Chip Design Services to address redundancy, incorporate alternative splicing and consider specificity and cross-homology while developing content and designs for the genome collections. Sigma-Genosys manufactures the products using its patented Abacus(TM) oligo synthesis platform and technologies. The products are co-marketed by both parties under a revenue sharing agreement. Customers of the OligoLibraries will be able to access certain gene sequences and other information relating to OligoLibraries through Compugen's LabOnWeb (www.labonweb.com) life science Internet research engine.
These genome libraries have been available under a limited early access program within Johns Hopkins University, the Medical Research Council, UK, the National Institutes of Health, National University of Singapore, National Cancer Institute's Advanced Technology Center at Gaithersburg, Maryland and the University of North Carolina.
The public launch of OligoLibraries now provides the life sciences research community with access to oligonucleotide collections for high throughput gene expression analysis, drug discovery and functional assays.
"These new oligonucleotide collections, utilizing Sigma-Genosys' expertise in long oligo production and Compugen's superior computational biology, provide the researcher with a more accurate and informative look at the human, mouse and rat genomes," said David Julien, President of the Biotechnology division of Sigma-Aldrich.
"Our collaboration with a market leader such as Sigma-Aldrich allows us to deliver the highest understanding of the human, mouse and rat genomes for the analysis of gene function. Together we are able to offer a high-quality manufacturing process combined with data precision and design accuracy, creating the best product currently available," said Mor Amitai, Ph.D., President and Chief Executive Officer of Compugen. "We are encouraged by the early market enthusiasm and have received positive feedback from initial results obtained by several early access customers," he added.
Other news from the department science
![[Fe]-hydrogenase catalysis visualized using para-hydrogen-enhanced nuclear magnetic resonance spectroscopy](https://img.chemie.de/Portal/News/675fd46b9b54f_sBuG8s4sS.png?tr=w-712,h-534,cm-extract,x-0,y-16:n-xl)
These products might interest you
Milli-Q® Services / MyMilli-Q™ by Merck Life Science
Services & Support for Water Purification Systems
Quality Care, Delivered. In Person & Online
Good Weighing Practice by Mettler-Toledo
Your Concrete Weighing Quality Assurance Plan
GWP Verification service
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
